{"symbol":"REGN","fiscalQuarter":"Q3-2016","reportDate":"2016-11-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2016","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.6%","keyNumbers":[{"metric":"EPS","actual":"$3.13","expected":"N/A","surprise":"+38.19%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing investment in research and development."],"summary":"Overall, management expressed confidence in their product pipeline and future growth. They acknowledged challenges but remain focused on innovation."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, beating expectations by over 38%, led to a positive stock reaction, with shares rising 1.6%. The company continues to focus on its product pipeline and innovation, which may support future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2016 earnings: EPS beat by 38.19%. Stock up 1.6%. Full breakdown."}}